SpringWorks Therapeutics 주식 주식분석 | 주식가격 | 뉴스 | SWTX | US85205L1070 | A2PRLN | 2025년 10월

날짜	SpringWorks Therapeutics 주식 가격
	0 undefined
	46.99 undefined
	46.99 undefined

날짜	SpringWorks Therapeutics 매출	SpringWorks Therapeutics EBIT	SpringWorks Therapeutics 이익
2030e	1.27 조. undefined	0 undefined	265.05 백만 undefined
2029e	1.06 조. undefined	76.3 백만 undefined	120.62 백만 undefined
2028e	897.75 백만 undefined	148.26 백만 undefined	167.87 백만 undefined
2027e	805.94 백만 undefined	131.71 백만 undefined	90.85 백만 undefined
2026e	586.68 백만 undefined	-116.22 백만 undefined	-113.53 백만 undefined
2025e	334.05 백만 undefined	-235.65 백만 undefined	-211.27 백만 undefined
2024	191.59 백만 undefined	-278.13 백만 undefined	-258.13 백만 undefined
2023	5.45 백만 undefined	-343.01 백만 undefined	-325.1 백만 undefined
2022	0 undefined	-280.67 백만 undefined	-277.42 백만 undefined
2021	0 undefined	-173.47 백만 undefined	-173.91 백만 undefined
2020	35 백만 undefined	-46.32 백만 undefined	-45.57 백만 undefined
2019	0 undefined	-59.24 백만 undefined	-50.58 백만 undefined
2018	0 undefined	-18.49 백만 undefined	-17.81 백만 undefined
2017	0 undefined	-4.66 백만 undefined	-4.64 백만 undefined

2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e	2028e	2029e	2030e
0	0	0	0.04	0	0	0.01	0.19	0.33	0.59	0.81	0.9	1.06	1.27
-	-	-	-	-	-	-	3,720.00	74.87	75.45	37.37	11.43	18.62	19.17
-	-	-	511.43	-	-	100.00	93.72	53.59	30.55	22.24	19.96	16.82	14.12
0	0	0	0	0	0	5	179	0	0	0	0	0	0
-4	-17	-50	-45	-173	-277	-325	-258	-211	-113	90	167	120	265
-	325.00	194.12	-10.00	284.44	60.12	17.33	-20.62	-18.22	-46.45	-179.65	85.56	-28.14	120.83
41.88	41.88	43	43.3	48.5	53.29	63.12	74.13	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-

2017	2018	2019	2020	2021	2022	2023	2024

10.3	45.6	327.7	508.5	373.5	592.2	479.2	307.99
0	0	0	0	0	0	5.93	46.24
0	0	0	0	0	0	0	0
0	0	0	0	0	0	3.1	10.21
0.3	1.4	3.7	4.9	9.4	7.5	12.68	16.03
10.6	47	331.4	513.4	382.9	599.7	500.91	380.47
0	0.3	0.8	3	4.2	18.3	24.09	26.66
0	0	1	57.2	62.1	9	185.34	158.12
0	0	0	0	0	0	0	0
0	0	0	0	0	0	11.2	15.56
0	0	0	0	0	0	0	0
0	1	1.7	2.6	3.3	3.2	4.25	6.47
0	1.3	3.5	62.8	69.6	30.5	224.88	206.81
10.6	48.3	334.9	576.2	452.5	630.2	725.79	587.28

14.6	64.9	0	0	0	0	0.01	0.01
0	0	0.4	0.68	0.72	1.13	1.52	1.65
-4.6	-22.5	-73	-118.6	-292.5	-569.9	-895.03	-1,153.17
0	0	0	0	-0.3	-0.8	1.19	0.3
0	0	0	0	0	0	0	0
10	43.5	322.1	557	422.4	559.5	630.36	493.68
0.3	0.8	2.7	1.4	3.4	8	7.4	12.25
0.4	2.6	9	16.3	26.5	39.7	66.63	87.74
0	0.3	0.4	0	0	3.3	4.14	0
0	0	0	0	0	0	0	0
0	0	0	1.4	1.16	0.48	0	0
0.7	3.7	12.1	19.1	31.06	51.48	78.17	99.99
0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0
0	1.2	0.8	1.5	0.1	21	21.4	6.18
0	1.2	0.8	1.5	0.1	21	21.4	6.18
0.7	4.9	12.9	20.6	31.16	72.48	99.57	106.17
10.7	48.4	335	577.6	453.56	631.98	729.93	599.86

2017	2018	2019	2020	2021	2022	2023
-4	-17	-58	-45	-173	-277	-325
0	0	0	0	0	0	1,000
0	0	0	0	0	0	0
0	2	4	1	5	38	0
2	2	8	21	78	149	195
0	0	0	0	0	0	0
0	0	0	0	0	0	0
-2	-14	-47	-32	-127	-161	-222
0	0	0	0	-2	-10	-7
0	0	-4	-418	83	-215	34
0	0	-3	-418	85	-205	42
0	0	0	0	0	0	0
0	0	0	0	0	0	0
12	50	333	270	1	340	296
12	50	333	270	1	340	296
-	-	-	-	-	-	-
0	0	0	0	0	0	0
10	35	282	-180	-43	-36	108
-2.28	-14.46	-48.11	-32.83	-129.9	-171.76	-230.18
0	0	0	0	0	0	0

SpringWorks Therapeutics 브루토마진	SpringWorks Therapeutics 이익 마진	SpringWorks Therapeutics EBIT-마진	SpringWorks Therapeutics 이익 마진
2030e	93.45 %	0 %	20.9 %
2029e	93.45 %	7.17 %	11.34 %
2028e	93.45 %	16.51 %	18.7 %
2027e	93.45 %	16.34 %	11.27 %
2026e	93.45 %	-19.81 %	-19.35 %
2025e	93.45 %	-70.54 %	-63.25 %
2024	93.45 %	-145.17 %	-134.73 %
2023	92.25 %	-6,297.28 %	-5,968.5 %
2022	93.45 %	0 %	0 %
2021	93.45 %	0 %	0 %
2020	93.45 %	-132.34 %	-130.2 %
2019	93.45 %	0 %	0 %
2018	93.45 %	0 %	0 %
2017	93.45 %	0 %	0 %

날짜	SpringWorks Therapeutics 주당 매출	SpringWorks Therapeutics EBIT 당 주식	SpringWorks Therapeutics 주당 이익
2030e	16.83 undefined	0 undefined	3.52 undefined
2029e	14.13 undefined	0 undefined	1.6 undefined
2028e	11.92 undefined	0 undefined	2.23 undefined
2027e	10.7 undefined	0 undefined	1.21 undefined
2026e	7.79 undefined	0 undefined	-1.51 undefined
2025e	4.44 undefined	0 undefined	-2.81 undefined
2024	2.58 undefined	-3.75 undefined	-3.48 undefined
2023	0.09 undefined	-5.43 undefined	-5.15 undefined
2022	0 undefined	-5.27 undefined	-5.21 undefined
2021	0 undefined	-3.58 undefined	-3.59 undefined
2020	0.81 undefined	-1.07 undefined	-1.05 undefined
2019	0 undefined	-1.38 undefined	-1.18 undefined
2018	0 undefined	-0.44 undefined	-0.43 undefined
2017	0 undefined	-0.11 undefined	-0.11 undefined

EPS-예상치	EPS-실제	보고 분기
-0.82	-1.11 (-35.47 %)	2025 Q1
-0.72	-1.04 (-44.63 %)	2024 Q4
-0.77	-0.72 (6.2 %)	2024 Q3
-1.14	-0.54 (52.52 %)	2024 Q2
-1.2	-1.18 (1.26 %)	2024 Q1
-1.27	-1.45 (-14.6 %)	2023 Q4
-1.36	-1.27 (6.38 %)	2023 Q3
-1.29	-1.25 (2.89 %)	2023 Q2
-1.27	-1.18 (6.85 %)	2023 Q1
-1.25	-1.17 (6.11 %)	2022 Q4
-1.34	-1.37 (-1.76 %)	2022 Q3
-1.23	-1.41 (-14.88 %)	2022 Q2
-1.04	-1.26 (-20.71 %)	2022 Q1
-0.9	-1.15 (-28.41 %)	2021 Q4
-0.78	-0.84 (-8.08 %)	2021 Q3
-0.69	-0.97 (-41.52 %)	2021 Q2
-0.52	-0.62 (-19.18 %)	2021 Q1
-0.1	0.3 (400 %)	2020 Q4
-0.49	-0.51 (-4.53 %)	2020 Q3
-0.37	-0.47 (-27.23 %)	2020 Q2
-0.39	-0.37 (4.54 %)	2020 Q1
-0.38	-0.39 (-3.7 %)	2019 Q4
-0.48	-1.77 (-271.3 %)	2019 Q3

%-지분	이름	주식	변경
9.44940 %	The Vanguard Group, Inc.	7,117,286	48,423
7.14855 %	BlackRock Institutional Trust Company, N.A.	5,384,291	110,877
5.45300 %	Glazer Capital, LLC	4,107,199	4,107,199
4.00154 %	Fidelity Investments Canada ULC	3,013,959	3,013,959
3.97504 %	State Street Global Advisors (US)	2,994,000	77,659
3.46664 %	TIG Advisors, L.L.C.	2,611,074	2,359,400
2.91772 %	Goldman Sachs & Company, Inc.	2,197,623	1,659,782
2.81144 %	Beryl Capital Management, LLC	2,117,575	2,117,575
2.72523 %	Magnetar Capital Partners LP	2,052,642	2,052,642
2.58068 %	First Trust Capital Management L.P.	1,943,767	1,915,064
2.40987 %	Norges Bank Investment Management (NBIM)	1,815,111	1,628,608
2.37580 %	Geode Capital Management, L.L.C.	1,789,449	73,997
2.16394 %	Barclays Bank PLC	1,629,877	701,064
2.11276 %	Citi Investment Research (US)	1,591,334	1,449,188
2.10185 %	NexPoint Asset Management, L.P	1,583,116	1,583,116
1.87973 %	AQR Capital Management, LLC	1,415,809	1,351,073
1.83951 %	UBS O'Connor LLC	1,385,517	1,346,549
1.79296 %	AllianceBernstein L.P.	1,350,456	1,253,369
1.64652 %	BlackRock Financial Management, Inc.	1,240,158	690,786
1.52549 %	Alpine Associates Management Inc.	1,149,000	949,500
1.51905 %	Gabelli Funds, LLC	1,144,151	1,061,841
1.33218 %	Principal Global Investors (Equity)	1,003,400	-60,709
1.32767 %	Pentwater Capital Management LP	1,000,000	500,000
1.30571 %	Medical Strategy GmbH	983,463	-1,400
1.05575 %	Whitebox Advisors, L.L.C.	795,191	795,191
1.04548 %	Trium Capital LLP	787,459	787,459
1.01636 %	Kryger Capital Limited	765,522	683,859
1.00982 %	Renaissance Technologies LLC	760,600	574,700
0.99643 %	Morgan Stanley & Co. LLC	750,513	-58,298
0.93649 %	Balyasny Asset Management LP	705,364	88,636
0.93405 %	Water Island Capital, LLC	703,525	85,804
0.91277 %	Harvest Management, LLC	687,500	544,000
0.85635 %	Oddo BHF Asset Management S.A.S	645,000	645,000
0.81920 %	ArrowMark Colorado Holdings, LLC	617,024	-842,052
0.80042 %	Islam Saqib	602,880	0
0.78634 %	Northern Trust Investments, Inc.	592,272	3,647
0.78264 %	J.P. Morgan Securities plc	589,487	583,020
0.77005 %	RBC Dominion Securities, Inc.	580,000	579,810
0.75995 %	Sand Grove Capital Management LLP	572,392	572,392
0.72625 %	Hudson Bay Capital Management LP	547,010	13,401
0.72339 %	Millennium Management LLC	544,856	40,988
0.66648 %	Soros Fund Management, L.L.C.	501,989	45,157
0.64375 %	Susquehanna International Group, LLP	484,874	-138,789
0.58019 %	Woodline Partners LP	437,000	-1,707,814
0.57438 %	Charles Schwab Investment Management, Inc.	432,624	-182,262
0.57011 %	Morgan Stanley Investment Management Inc. (US)	429,405	429,378
0.52162 %	UBS Financial Services, Inc.	392,884	-222,846
0.50943 %	Janus Henderson Investors	383,701	356,676
0.47132 %	Healthcare Of Ontario Pension Plan	355,000	355,000
0.46654 %	P. Schoenfeld Asset Management LP	351,400	351,400
0.42830 %	AQR Arbitrage, LLC	322,593	322,593
0.41610 %	Verition Fund Management LLC	313,408	154,624
0.41557 %	BlackRock Investment Management (UK) Ltd.	313,004	195,638
0.37595 %	BofA Global Research (US)	283,168	-240,364
0.37135 %	LMR Partners LLP	279,700	239,700
0.36790 %	JPMorgan Private Bank (United States)	277,100	244,558
0.33805 %	J.P. Morgan Securities LLC	254,617	254,022
0.33192 %	Vestcor Inc	250,000	190,000
0.32793 %	Syquant Capital S.A.S	247,000	247,000
0.32240 %	Credit Industriel et Commercial SA	242,834	242,834
0.28776 %	BlackRock Investment Management, LLC	216,741	48,988
0.28678 %	PSquared Asset Management AG	216,000	216,000
0.27120 %	Squarepoint Capital LLP	204,271	204,271
0.26699 %	D. E. Shaw & Co., L.P.	201,100	-1,462,383
0.26584 %	Chicago Capital Management, LLC	200,230	200,230
0.24634 %	Marshall Wace LLP	185,540	134,602
0.23234 %	PICTON Investments	175,000	175,000
0.22798 %	Prelude Capital Management, LLC	171,716	140,533
0.22350 %	GLG LLC	168,337	156,484
0.21870 %	Nuveen LLC	164,724	-133,909
0.21765 %	La Française AM	163,935	163,935
0.19757 %	Carmignac Gestion	148,806	-16,701
0.18425 %	BNY Mellon Asset Management	138,776	13,566
0.17599 %	Palisades Investment Partners, LLC	132,555	-3,923
0.17472 %	Tokio Marine Asset Management Co., Ltd.	131,600	131,600
0.16370 %	Nomura Asset Management Co., Ltd.	123,300	58,800
0.15136 %	Rafferty Asset Management LLC	114,006	3,080
0.15058 %	Rhumbline Advisers Ltd. Partnership	113,415	7,994
0.14693 %	UBS Asset Management (Switzerland)	110,671	53,931
0.13646 %	Edris (Badreddin)	102,781	0
0.13463 %	Twin Capital Management, LLC	101,402	-18,426
0.13284 %	BNP Paribas Asset Management UK Limited	100,052	0
0.12889 %	First Trust Advisors L.P.	97,078	52,718
0.12868 %	Wolverine Asset Management, LLC	96,924	96,924
0.11930 %	Bardin Hill Investment Partners LP	89,853	56,553
0.11484 %	Boussard & Gavaudan Investment Management LLP	86,500	0
0.11012 %	Lynch (Daniel S)	82,944	0
0.10709 %	GLG Partners LP	80,658	74,639
0.10333 %	Goldman Sachs Asset Management, L.P.	77,826	-4,971
0.10129 %	New York State Common Retirement Fund	76,294	-289,566
0.10086 %	Weiss Asset Management	75,969	16,349
0.10009 %	Legal & General Investment Management Ltd.	75,391	8,808
0.09892 %	Citadel Advisors LLC	74,505	-177,009
0.09860 %	Tang Capital Management, LLC	74,265	0
0.09402 %	Jane Street Capital, L.L.C.	70,814	-94,073
0.09197 %	T. Rowe Price International Ltd	69,269	-3,705
0.08884 %	Parametric Portfolio Associates LLC	66,911	-15,397
0.08879 %	Voya Investment Management LLC	66,880	-809,667
0.08488 %	Artia Global Partners LP	63,930	10,000
0.07688 %	TD Securities, Inc.	57,903	-12,107

이름	관계	이주간 상관관계	원월 상관관계	삼개월 상관계수	여섯달 상관관계	일년간 상관관계	이년 상관관계
Personalis	공급업체고객	0,79	0,96	0,91	0,83	0,85	0,55
Jazz Pharmaceuticals	공급업체고객	0,41	0,87	0,58	-0,42	0,21	0,58
Pfizer	공급업체고객	0,35	0,83	-0,09	0,18	-0,63	-0,12
BeiGene	공급업체고객	0,33	0,75	0,70	0,77	0,69	0,71
Johnson & Johnson	공급업체고객	0,32	-0,18	-0,75	-0,82	-0,46	0,20
Seagen	공급업체고객	0,31	0,04	0,52	0,53	0,51	0,09
Precision BioSciences	공급업체고객	0,27	0,87	0,85	0,80	0,81	0,75
GlaxoSmithKline	공급업체고객	0,26	0,59	-0,69	-0,68	-0,74	-0,65
AbbVie	공급업체고객	0,24	0,62	-0,32	-0,69	-0,73	-0,14
Allogene Therapeutics	공급업체고객	0,13	0,87	0,76	0,75	0,84	0,09

What values and corporate philosophy does SpringWorks Therapeutics represent?

SpringWorks Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for patients with severe rare diseases and cancer. The company's core values include dedication, integrity, and collaboration in their pursuit of discovering novel treatments. With a patient-centric approach, SpringWorks Therapeutics aims to improve the lives of individuals affected by these debilitating conditions. They prioritize scientific excellence and ethical practices to deliver safe and effective therapies. Through strategic partnerships and pioneering research, the company strives to bring hope and transformative solutions to patients in need. SpringWorks Therapeutics Inc is committed to making a lasting impact in the lives of patients and their families.

In which countries and regions is SpringWorks Therapeutics primarily present?

SpringWorks Therapeutics Inc is primarily present in the United States.

What significant milestones has the company SpringWorks Therapeutics achieved?

Some significant milestones achieved by SpringWorks Therapeutics Inc include the approval of their lead product candidate, Nirogacestat, for the treatment of desmoid tumors by the U.S. FDA. The company also received Fast Track and Orphan Drug designations for Nirogacestat, which further highlights its potential in addressing unmet medical needs. Additionally, SpringWorks Therapeutics Inc has successfully initiated multiple clinical trials evaluating various therapies for rare cancers and genetic diseases. These accomplishments demonstrate the company's commitment towards advancing innovative treatments and improving patients' lives.

What is the history and background of the company SpringWorks Therapeutics?

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing life-changing therapies for patients with severe rare diseases and cancer. Founded in 2017, SpringWorks Therapeutics is committed to delivering innovative treatments by leveraging its strategic collaborations and advanced drug development expertise. With a diverse pipeline of investigational therapies, the company aims to address unmet medical needs and improve patients' lives globally. SpringWorks Therapeutics Inc has made significant progress in its mission to transform the lives of patients through its dedication to scientific excellence and groundbreaking research in the field of precision medicine.

Who are the main competitors of SpringWorks Therapeutics in the market?

The main competitors of SpringWorks Therapeutics Inc in the market include companies like Novartis, Pfizer, and Roche.

In which industries is SpringWorks Therapeutics primarily active?

SpringWorks Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of SpringWorks Therapeutics?

The business model of SpringWorks Therapeutics Inc. is focused on developing and commercializing innovative targeted therapies for patients with severe rare diseases and cancer. The company aims to identify promising drug candidates and advance them through clinical development to address unmet medical needs. SpringWorks Therapeutics Inc. collaborates with both academic institutions and industry partners to leverage its expertise and optimize the development of potential treatments. By utilizing targeted therapies, the company aims to provide effective and personalized solutions for patients, with a focus on improving their overall quality of life.

SpringWorks Therapeutics 2025의 P/E 비율은 얼마입니까?

SpringWorks Therapeutics에 대한 현재 주가 수익 비율을 계산할 수 없습니다.

SpringWorks Therapeutics 2025의 KUV는 얼마입니까?

SpringWorks Therapeutics에 대한 현재 KUV는 계산할 수 없습니다.

SpringWorks Therapeutics의 AlleAktien 품질 점수는 얼마인가요?

SpringWorks Therapeutics에 대한 AlleAktien 품질 점수는 3/10입니다.

SpringWorks Therapeutics 2025의 매출은 얼마인가요?

예상되는 SpringWorks Therapeutics 매출은 334.05 백만 USD입니다.

SpringWorks Therapeutics 2025의 이익은 얼마인가요?

예상되는 SpringWorks Therapeutics 이익은 -211.27 백만 USD입니다.

SpringWorks Therapeutics은 무엇을 하나요?

SpringWorks Therapeutics is a biopharmaceutical company focused on developing therapeutics for patients with rare severe diseases. The business model involves developing innovative therapies with high medical necessity and making them accessible to the market. The company specializes in three main areas: oncology, inherited metabolic disorders, and neurological disorders. SpringWorks aims to develop new and effective therapies for each of these diseases. In the oncology sector, SpringWorks utilizes its expertise in drug discovery and development to create innovative cancer therapies. One of the leading products is Nirogacestat, a Notch pathway inhibitor that has the potential to be used against solid tumors that do not respond to other forms of therapy. In the inherited metabolic disorders division, SpringWorks is working on developing therapies for patients with rare diseases such as Niemann-Pick Type C syndrome. The company has partnered with Cydan Development, a company specializing in developing drugs for rare genetic disorders, for this purpose. In the field of neurological disorders, SpringWorks aims to develop therapies for patients with rare genetic diseases such as epilepsy and Huntington's disease. The company has initiated a collaboration with the Hospital for Sick Children in Toronto for this purpose. The company also has an innovative technology called "Biomarker Relocation" which allows for the identification of patients with certain rare diseases that are otherwise difficult to diagnose and treat. The technology is currently a significant component of SpringWorks' research and development efforts. In recent years, the company has raised capital through investments and collaborations for its business model. The funding has been based on venture capital from leading companies including Novartis Venture Fund, Pfizer Ventures, and OrbiMed. SpringWorks' business strategy also includes partnerships with other companies and research institutions. One collaboration, for example, exists with the Memorial Sloan Kettering Cancer Center, a leading institution in cancer research. The vision of SpringWorks is to play a leading role in the development of therapeutics for patients with rare diseases and to meet the medical need in this area. The company strives to improve the lives of patients with rare diseases and provide them with an optimal medication that alleviates their condition and enhances their quality of life. Overall, SpringWorks is an emerging player in the biotech industry, developing innovative therapeutics to address the needs of patients with rare diseases. With a presence in multiple medical specialties and a strong financing base, the company is poised to secure a position at the forefront of the biotech industry.

SpringWorks Therapeutics 배당금은 얼마입니까?

SpringWorks Therapeutics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

SpringWorks Therapeutics이 얼마나 자주 배당을 지급하나요?

SpringWorks Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

SpringWorks Therapeutics ISIN이 무엇입니까?

SpringWorks Therapeutics의 ISIN은 US85205L1070입니다.

SpringWorks Therapeutics WKN은 무엇인가요?

SpringWorks Therapeutics의 WKN은 A2PRLN입니다.

SpringWorks Therapeutics 티커는 무엇인가요?

SpringWorks Therapeutics의 티커는 SWTX입니다.

SpringWorks Therapeutics이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 SpringWorks Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 SpringWorks Therapeutics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

SpringWorks Therapeutics의 배당 수익률은 얼마입니까?

SpringWorks Therapeutics의 현재 배당 수익률은 입니다.

SpringWorks Therapeutics의 배당금은 언제 지급되나요?

SpringWorks Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

SpringWorks Therapeutics의 배당금은 얼마나 안전한가요?

SpringWorks Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

SpringWorks Therapeutics의 배당금은 얼마입니까?

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

SpringWorks Therapeutics이(가) 속해 있는 섹터는 어디인가요?

SpringWorks Therapeutics은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von SpringWorks Therapeutics kaufen, um die vorherige Dividende zu erhalten?

SpringWorks Therapeutics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

SpringWorks Therapeutics의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

SpringWorks Therapeutics의 2024년도 배당금은 얼마였습니까?

2024년에 SpringWorks Therapeutics는 0 USD를 배당금으로 지급했습니다.

SpringWorks Therapeutics는 어떤 화폐로 배당금을 지급하나요?

SpringWorks Therapeutics의 배당금은 USD에 지급됩니다.

Scope 1 - 직접 방출
스코프 2 - 구매한 에너지로부터의 간접적인 배출
Scope 3 - 가치 창출 체인 내의 간접 배출
총 CO₂ 배출량
CO₂ 감소 전략
석탄 에너지
원자력
동물 실험
펠츠 & 레더
살충제
팜 오일
담배
유전자 변형 생물체
기후 개념
지속 가능한 임업
재활용 규정
환경 친화적인 포장
위험물질
연료 소비량과 효율성
물 사용량 및 효율성

여성 직원 비율
관리 직위에서의 여성 비율
아시아 직원 비율
아시아 경영진 비율
히스패닉/라티노 직원 비율
히스패닉/라티노 관리 부문 지분
흑인 직원 비율
블랙 매니지먼트 지분
흰색 종업원의 비율
화이트 매니지먼트 지분
성인 콘텐츠
알코올
무기
총기
도박
군사 계약
인권 개념
개인정보 보호 정책
작업 및 건강 보호
카톨릭

환경 보고
이해관계자 참여
콜백 정책
카르텔법

SpringWorks Therapeutics 티커	SpringWorks Therapeutics FIGI
SWTX:US	BBG00Q011TW9
SWTX:UA	BBG00Q011WG0
SWTX:UC	BBG00Q011WH9
SWTX:UN	BBG00Q011WK5
SWTX:UP	BBG00Q011WL4
SWTX:UB	BBG00Q011WN2
SWTX:UM	BBG00Q011WQ9
SWTX:UX	BBG00Q011WR8
SWTX:UD	BBG00Q011WX1
SWTX:UW	BBG00Q011WZ9
SWTX:UF	BBG00Q011X05
SWTX:VY	BBG00Q011X14
SWTX:VJ	BBG00Q011X23
SWTX:VK	BBG00Q011X32
SWTX:VF	BBG00Q011X41
SWTX:VG	BBG00X1PJ0B7
SWTX:VP	BBG00X1SYDQ0
SWTXUSD:XH	BBG0116NTVG2
SWTXUSD:XF	BBG0116NTVJ9
SWTXUSD:XE	BBG0116NTVL6
SWTXUSD:XL	BBG0116NTVN4
SWTXUSD:XG	BBG0116NTVP2
SWTXUSD:XO	BBG0116NTVQ1
SWTXUSD:XA	BBG0116NTVV5
SWTXUSD:XT	BBG0116NTVX3
SWTXUSD:XW	BBG0116NTVY2
SWTXUSD:XU	BBG0116NTVZ1
SWTXUSD:XV	BBG0116NTW16
SWTXUSD:XM	BBG0116NTW25
SWTXUSD:EU	BBG0116NTWC4
SWTXGBP:XH	BBG012Y8GMV9
SWTXGBP:XF	BBG012Y8GMX7
SWTXGBP:XE	BBG012Y8GMZ5
SWTXGBP:XL	BBG012Y8GN10
SWTXGBP:XG	BBG012Y8GN29
SWTXGBP:XO	BBG012Y8GN38
SWTXGBP:XA	BBG012Y8GN74
SWTXGBP:XT	BBG012Y8GN92
SWTXGBP:XW	BBG012Y8GNB9
SWTXGBP:XU	BBG012Y8GNC8
SWTXGBP:XV	BBG012Y8GNG4
SWTXGBP:XM	BBG012Y8GNH3
SWTXGBP:EU	BBG012Y8GNY4

한눈에 저평가된 주식을 인식하세요

SpringWorks Therapeutics 주식 SWTX

가격

가격

티커SWTX

ISINUS85205L1070

WKNA2PRLN

SpringWorks Therapeutics 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

SpringWorks Therapeutics 주가 이력

SpringWorks Therapeutics 주식 매출, EBIT, 이익

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

SpringWorks Therapeutics 매출, 이익 및 EBIT 역사

SpringWorks Therapeutics 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

SpringWorks Therapeutics 주식 마진

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

SpringWorks Therapeutics 마진 역사

SpringWorks Therapeutics 주식 매출, EBIT, 주당 순이익

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

SpringWorks Therapeutics 매출, 이익 및 EBIT 주당 역사

SpringWorks Therapeutics 주식 및 주식 분석

한눈에 과소평가된 주식을 인식하세요.

SpringWorks Therapeutics Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

SpringWorks Therapeutics 역사적인 P/E, EBIT 및 P/S에 따른 평가

한눈에 과소평가된 주식을 인식하세요.

SpringWorks Therapeutics 주식 수량

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

한눈에 과소평가된 주식을 인식하세요.

SpringWorks Therapeutics 수익 예상

SpringWorks Therapeutics 수익 놀라움

Eulerpool ESG Scorecard© SpringWorks Therapeutics 주식을 위해

Eulerpool World ESG Rating (EESG©)

15/ 100

🌱 Environment

👫 Social

🏛️ Governance

환경

티커
SWTX

ISIN
US85205L1070

WKN
A2PRLN